June 23, 2020
Bristol-Myers Squibb K.K. said on June 22 that its affiliate Celgene K.K. has filed the CAR-T cell therapy lisocabtagene maraleucel (JCAR017/liso-cel) in Japan for the treatment of relapsed/refractory large B-cell lymphoma. The submission made under the category of regenerative medicine...read more